Literature DB >> 21418343

Comparison between major histocompatibility complex class II tetramer staining and surface expression of activation markers for the detection of allergen-specific CD4⁺ T cells.

M Bonvalet1, E Wambre, H Moussu, S Horiot, W W Kwok, A Louise, D Ebo, C Hoarau, L Van Overtvelt, V Baron-Bodo, P Moingeon.   

Abstract

BACKGROUND: Major histocompatibility complex (MHC) class II tetramers (tetramers) allow to detect allergen-specific CD4(+) T cells at a single-cell level. Limits to this technology include HLA restriction and the need to identify immunodominant T cell epitopes.
OBJECTIVE: Assessing the expression of various activation markers following allergen stimulation to replace tetramer staining.
METHODS: Peripheral blood mononuclear cells (PBMCs) from 25 birch pollen, grass pollen or house dust mite allergic individuals were stimulated with peptide mixes encompassing immunodominant epitopes from corresponding major allergens. After 2 weeks of in vitro amplification, cells were stained with both the appropriate tetramer and antibodies directed to CD25, CD30, CD39, CD69, CD137, CD154, GITR, HLA-DR and ICOS, before FACS analysis.
RESULTS: Following allergen stimulation, percentages of tetramer(+) cells among CD4(+) CD154(+) cells range from 5% to 87%, depending upon donors. As for CD154, a large inter-individual variability is observed in terms of surface expression for all activation markers tested in allergen-stimulated PBMCs. T cells reactive with either tetramers (0.4-10.4% CD4(+) T cells) or anti-marker antibodies (2.2-32.7% CD4(+) T cells), but not both, are observed, reflecting the presence of anergic as well as non-specifically activated cells. Tetramer(+) /marker(+) , tetramer(+) /marker(-) and tetramer(-) /marker(+) cells were compared for their capacity to express cytokines, demonstrating that only the former represent bona fide allergen-specific activated CD4(+) T cells, based upon a higher expression of cytokines or corresponding genes in presence of the allergen. CONCLUSION AND CLINICAL RELEVANCE: No strict correlation exists between tetramer staining and the expression of multiple activation markers in stimulated CD4(+) T cells. Dual staining allows to discriminate functional tetramer(+) /marker(+) vs. anergic (tetramer(+) /marker(-) ) allergen-specific T cells or non-specifically activated (tetramer(-) /marker(+) ) T cells. Combining tetramer staining with the detection of activation markers helps understanding patient heterogeneity regarding specific CD4(+) T cell responses. This approach has immediate relevance for monitoring immune changes induced during specific immunotherapy.
© 2011 Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21418343     DOI: 10.1111/j.1365-2222.2011.03708.x

Source DB:  PubMed          Journal:  Clin Exp Allergy        ISSN: 0954-7894            Impact factor:   5.018


  9 in total

Review 1.  New strategies for allergen T cell epitope identification: going beyond IgE.

Authors:  Véronique Schulten; Bjoern Peters; Alessandro Sette
Journal:  Int Arch Allergy Immunol       Date:  2014-11-15       Impact factor: 2.749

Review 2.  Major Histocompatibility Complex Class II Dextramers: New Tools for the Detection of antigen-Specific, CD4 T Cells in Basic and Clinical Research.

Authors:  C Massilamany; B Krishnan; J Reddy
Journal:  Scand J Immunol       Date:  2015-11       Impact factor: 3.487

3.  Definition of a pool of epitopes that recapitulates the T cell reactivity against major house dust mite allergens.

Authors:  D Hinz; C Oseroff; J Pham; J Sidney; B Peters; A Sette
Journal:  Clin Exp Allergy       Date:  2015-10       Impact factor: 5.018

4.  Immunoproteomic analysis of house dust mite antigens reveals distinct classes of dominant T cell antigens according to function and serological reactivity.

Authors:  Carla Oseroff; Lars H Christensen; Luise Westernberg; John Pham; Jerome Lane; Sinu Paul; Jason Greenbaum; Thomas Stranzl; Gitte Lund; Ilka Hoof; Jens Holm; Peter A Würtzen; Kåre H Meno; April Frazier; Veronique Schulten; Peter S Andersen; Bjoern Peters; Alessandro Sette
Journal:  Clin Exp Allergy       Date:  2016-11-07       Impact factor: 5.018

Review 5.  Allergen-Specific CD4(+) T Cells in Human Asthma.

Authors:  Morris F Ling; Andrew D Luster
Journal:  Ann Am Thorac Soc       Date:  2016-03

Review 6.  Strategies to query and display allergy-derived epitope data from the immune epitope database.

Authors:  Kerrie Vaughan; Bjoern Peters; Mark Larche; Anna Pomes; David Broide; Alessandro Sette
Journal:  Int Arch Allergy Immunol       Date:  2012-11-21       Impact factor: 2.749

7.  Sublingual immunotherapy: World Allergy Organization position paper 2013 update.

Authors:  Giorgio Walter Canonica; Linda Cox; Ruby Pawankar; Carlos E Baena-Cagnani; Michael Blaiss; Sergio Bonini; Jean Bousquet; Moises Calderón; Enrico Compalati; Stephen R Durham; Roy Gerth van Wijk; Désirée Larenas-Linnemann; Harold Nelson; Giovanni Passalacqua; Oliver Pfaar; Nelson Rosário; Dermot Ryan; Lanny Rosenwasser; Peter Schmid-Grendelmeier; Gianenrico Senna; Erkka Valovirta; Hugo Van Bever; Pakit Vichyanond; Ulrich Wahn; Osman Yusuf
Journal:  World Allergy Organ J       Date:  2014-03-28       Impact factor: 4.084

8.  Allergic asthma is distinguished by sensitivity of allergen-specific CD4+ T cells and airway structural cells to type 2 inflammation.

Authors:  Josalyn L Cho; Morris F Ling; David C Adams; Lucas Faustino; Sabina A Islam; Roshi Afshar; Jason W Griffith; Robert S Harris; Aylwin Ng; Giorgia Radicioni; Amina A Ford; Andre K Han; Ramnik Xavier; William W Kwok; Richard Boucher; James J Moon; Daniel L Hamilos; Mehmet Kesimer; Melissa J Suter; Benjamin D Medoff; Andrew D Luster
Journal:  Sci Transl Med       Date:  2016-10-05       Impact factor: 19.319

9.  Characterisation of CD154+ T cells following ex vivo birch allergen stimulation defines a close relationship between T cell subsets in healthy volunteers.

Authors:  Karen A Smith; Nicola J Gray; Elizabeth Cheek; Femi Saleh; Jo Lavender; Anthony J Frew; Florian Kern; Michael D Tarzi
Journal:  BMC Immunol       Date:  2013-03-22       Impact factor: 3.615

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.